High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Nanotechnology could improve our understanding of the pathophysiology of atherosclerosis
and contribute to the development of novel diagnostic and therapeutic strategies to further …

Background Patients with elevated triglyceride levels are at increased risk for ischemic
events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers …

Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but
few effective long-term treatments are available. In cardiovascular trials of inhibitors of …

Atherosclerosis is an immunoinflammatory pathological procedure in which lipid plaques
are formed in the vessel walls, partially or completely occluding the lumen, and is …

Background Little is known about the relationship between lipoprotein (a)[Lp (a)] and high-
sensitivity C-reactive protein (hsCRP) and their joint association with atherosclerotic …

A reliable, individualized, and dynamic surrogate of cardiovascular risk, synoptic for key
biologic mechanisms, could shorten the path for drug development, enhance drug cost …

Atherosclerosis, the underlying cause of cardiovascular disease (CVD), is a worldwide
cause of morbidity and mortality. Reducing ApoB-containing lipoproteins—chiefly, LDL (low …

Unprecedented advances in secondary prevention have greatly improved the prognosis of
cardiovascular diseases (CVDs); however, CVDs remain a leading cause of death globally …

Despite considerable advances in reducing the global burden of atherosclerotic
cardiovascular disease by targeting conventional risk factors, significant residual risk …